Quantum BioPharma Wins FDA Clearance for Phase 2 Lucid-MS Trial, Holds US$9.5M Cash With Runway to at Least October 2027

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) received FDA clearance on August 14, 2026 to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis, per the company's August 14, 2026 news release on GlobeNewswire. As of June 30, 2026, the company held US$9.5 million in combined cash, cash equivalents, and digital assets.

The investigational therapy is Lucid-21-302, known as Lucid-MS, designed to protect myelin by inhibiting protein arginine deiminase 2 (PAD2), an enzyme involved in myelin destabilization. That mechanism sets it apart from every currently approved MS disease-modifying therapy, which primarily modulate immune cell behavior to prevent relapses. Per the company's August 14, 2026 GlobeNewswire release, no FDA-approved MS therapy has demonstrated remyelinating or demyelination-preventing properties — a gap that defines Lucid-MS's clinical rationale.

"FDA clearance to proceed with our Lucid-MS Phase 2 trial is a transformative moment for Quantum and the result of years of dedicated scientific research," said Zeeshan Saeed, Chief Executive Officer of Quantum, per the Manila Times.

The US$9.5 million cash position as of June 30, 2026 is up from US$4.1 million as of December 31, 2025, per the same GlobeNewswire release. Management states that figure, at the current burn rate established during the first half of 2026, is sufficient to fund planned operations to at least October 2027.

"We brought total operating expenses down by more than 50% year-over-year in the second quarter, and our strengthened financial position assuming cash burn rate similar to the first half of 2026 provides a runway to at least October 2027 at our current budgeted spend," said Donal Carroll, Chief Financial Officer of Quantum, per the Manila Times.

Trial start-up activities are already underway, including study site selection, with enrollment and dosing expected to begin as soon as possible, per Multiple Sclerosis News Today. No enrollment timeline or patient-count target appears in the company's public disclosures reviewed for this article.

The primary progressive MS treatment segment is projected to grow from roughly $1.16 billion in 2025 to about $1.31 billion in 2026, and the broader global MS therapeutics market is expected to approach $38.62 billion by 2030, per sources cited in the company's web disclosure filing. The broader neuroprotection field has faced repeated setbacks, per the company's GlobeNewswire release and NeurologyLive reporting on the FDA clearance.

One note of caution on market data: share count figures from available sources conflict — StockAnalysis, retrieved in August 2026, shows 5.83 million shares outstanding, while ADVFN shows 6,398,647 shares. Given that discrepancy, market capitalization figures cited by third parties should be treated with care until the company clarifies its current share count in an official filing.

Site selection is in progress, with dosing to begin as soon as possible per the company's disclosures. The next material catalyst is the start of enrollment, which the company has not yet dated publicly.